The US Association for Accessible Medicines has spoken out against the Build Back Better Act, saying it “threatens the only segment of our health care system that consistently drives prices down for patients.”
AAM Speaks Out Against Build Back Better Bill
US Pricing Policy Could Unfairly Penalize Generics And Biosimilars Manufacturers
The US Association for Accessible Medicines has panned the Biden administration’s Build Back Better Act, which it says threatens patient access to affordable drugs in its current form.
More from Policy & Regulation
• By
During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.
• By
French generics and biosimilar body Gemme has welcomed a call from the country’s audit court to improve uptake for off-patent medicines.
• By
The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.
• By
The elimination of the policy division at the Office of Generic Drugs, tariffs, the Section 232 investigation, and a new executive order to promote lower drug prices seem to both cause and purport to solve the same problem: supply chain disruption.
More from Generics Bulletin
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.